Skip to main content
. 2018 Jan 5;13(1):e0189176. doi: 10.1371/journal.pone.0189176

Table 5. Clinical features, postoperative complications and adjuvant treatment as related to the development of lymphedema after 30 months of follow-up.

Lymphedema p-value
Yes No
N % n %
Groups 0.3980
 AE 11 30.6 25 69.4
 MLD 9 28.1 23 71.9
Age 20 55.1±17.5 48 59.2±13.0 0.4001
BMI (kg/m2) 20 28.07±5.96 48 28.37±5.96 0.7066
Seroma 0.4827
 Yes 6 33.3 19 40.4
 No 12 66.7 28 59.6
Dehiscence 0.9126*
 Yes 3 16.7 6 12.8
 No 15 83.3 41 87.2
Infection 0.2047
 Yes 6 33.3 13 27.7
 No 12 66.7 34 72.3
Neoadjuvant chemotherapy 0.5944
 Yes 15 75.0 25 52.1
 No 5 25.0 23 47.9
Adjuvant chemotherapy 0.9419
 Yes 16 80.0 25 54.3
 No 4 20.0 21 45.7
Radiotherapy 0.9440
 Yes 14 82.4 35 76.1
 No 3 17.6 11 23.9

Chi-Square test;

(*) Fisher’s Exact test;

SCF = supraclavicular fossa; SD = standard deviation